We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Ken Haas has spent 25 years in the management of both early-stage and public high technology and biotechnology companies. His primary role at Abingworth is to identify, invest in and provide support for portfolio companies. His current and past directorships include eFFECTOR, Gynesonics, Intellikine, SFJ Pharmaceuticals and Zogenix.
Ken was part of the founding management team at IntelliGenetics, one of the world’s first bioinformatics companies and CEO of IntelliCorp, a publicly-traded enterprise software company. At the beginning of his career he practiced as an attorney in the business and technology group of Heller, Ehrman, White & McAuliffe, and has been Co-Chair of the Advisory Council to the Neuroscience Institute at Stanford. He received his BA from Harvard College, an MA from the University of Sussex and a JD from Harvard Law School.
This speaker's sessions: